Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.4K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.

Cancer research communications·2026
Same author

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
Same author

Penile self-augmentation with Vaseline injection.

Urology case reports·2026
Same author

International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.

BJU international·2026
Same author

Emerging robotic platforms in partial nephrectomy: a comparative systematic review and network meta-analysis.

Journal of robotic surgery·2026
Same author

Single Port Robotic Radical Prostatectomy: A Propensity-matched Comparison of Transvesical Versus Extraperitoneal Approaches from the Single Port Advanced Research Consortium.

European urology oncology·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Faris Najdawi1, Rashid K Sayyid2, Thomas Ahlering3

  • 1Division of Urology, Cook County Health and Hospitals System, Chicago, IL, USA.

Current Oncology Reports
|March 31, 2026
PubMed
Summary
This summary is machine-generated.

Testosterone-sparing treatments offer a promising alternative to androgen deprivation therapy for biochemical recurrence (BCR) after prostatectomy. These strategies aim to maintain cancer control while avoiding testosterone suppression and its side effects in select patients.

Keywords:
Androgen deprivation therapyBiochemical recurrenceProstate cancerTestosterone-sparing treatment

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.1K

Related Experiment Videos

Last Updated: Apr 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.1K

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Biochemical recurrence (BCR) after radical prostatectomy affects up to one-third of patients, increasing risks of metastasis and mortality.
  • Androgen deprivation therapy (ADT) is standard but raises concerns about overtreatment and quality-of-life impairment in low- and intermediate-risk BCR.

Purpose of the Study:

  • To review contemporary testosterone-sparing treatment (TST) strategies for BCR.
  • To discuss patient selection, emerging therapeutics, and advanced imaging in TST for BCR.

Main Methods:

  • Review of current literature on TST for BCR.
  • Analysis of risk stratification tools, including genomic classifiers and AI models.
  • Evaluation of advanced imaging like PSMA-PET for staging and treatment guidance.

Main Results:

  • AI and genomic classifiers are improving treatment decisions for BCR.
  • PSMA-PET redefines staging and guides salvage radiation and metastasis-directed therapy.
  • Emerging TST strategies (e.g., enzalutamide, lifestyle interventions) show potential to delay or avoid ADT, maintaining cancer control with fewer toxicities.

Conclusions:

  • BCR management requires individualized strategies balancing oncologic outcomes and survivorship.
  • Testosterone-sparing approaches can be safe alternatives to ADT in carefully selected patients.
  • Further validation of biomarkers and AI tools will refine patient selection for TST.